NUTLEY, NJ — June 26, 2002 —
Roche and Gilead Sciences, Inc. announced that Roche has received approval from the European authorities to market Tamiflu® (oseltamivir phosphate) for the treatment of influenza in adults and children and the prevention of influenza in adolescents and adults.
Roche had received a positive recommendation for Tamiflu from the Committee for Proprietary Medicinal Products (CPMP) in March. Tamiflu has been available in the United States since it was approved by the U.S. Food and Drug Administration (FDA) in 1999, and has been prescribed to millions of people within the first two days of their symptoms, starting to help reduce the duration of their flu.
Tamiflu will be available to patients in time for the 2002-2003 influenza season in Europe thus playing an important role in the management of influenza. “Access to new antivirals such as Tamiflu is important for physicians and patients.
It means that the medical profession will have a new weapon to fight the influenza virus, which affects many people every year in Europe, knocking them flat,” commented Professor John Oxford, Barts and The London, Queen Mary’s School of Medicine and Dentistry, London, UK. In Europe, influenza can affect up to one in ten adults in a normal year, and this number can increase significantly during severe epidemics. In the United Kingdom, about 20,000 people died as a result of influenza and its complications in 2000. In the U.S., approximately 30 to 40 million Americans contract the flu virus each year.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!